Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort.

Visa fullständig post



Permalänk

http://hdl.handle.net/10138/321788

Citation

Luotola , K , Jyväkorpi , S , Urtamo , A , Pitkälä , K H , Kivimäki , M & Strandberg , T E 2020 , ' Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort. ' , Age and Ageing , vol. 49 , no. 2 , pp. 258-263 . https://doi.org/10.1093/ageing/afz138

Titel: Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort.
Författare: Luotola, Kari; Jyväkorpi, Satu; Urtamo, Annele; Pitkälä, Kaisu H.; Kivimäki, Mika; Strandberg, Timo E.
Upphovmannens organisation: HUS Heart and Lung Center
Department of Medicine
Clinicum
Department of General Practice and Primary Health Care
HUS Helsinki and Uusimaa Hospital District
HUS Internal Medicine and Rehabilitation
Teachers' Academy
Datum: 2020-03
Språk: eng
Sidantal: 6
Tillhör serie: Age and Ageing
ISSN: 0002-0729
DOI: https://doi.org/10.1093/ageing/afz138
Permanenta länken (URI): http://hdl.handle.net/10138/321788
Abstrakt: BACKGROUND: statin treatment has increased also among people aged 80 years and over, but adverse effects potentially promoting frailty and loss of resilience are frequent concerns. METHODS: in the Helsinki Businessmen Study, men born in 1919-34 (original n = 3,490) have been followed up since the 1960s. In 2011, a random subcohort of home-living survivors (n = 525) was assessed using questionnaires and clinical (including identification of phenotypic frailty) and laboratory examinations. A 7-year mortality follow-up ensued. RESULTS: we compared 259 current statin users (median age 82 years, interquartile range 80-85 years) with 266 non-users (83; 80-86 years). Statin users had significantly more multimorbidity than non-users (prevalencies 72.1% and 50.4%, respectively, P < 0.0001) and worse glucose status than non-users (prevalencies of diabetes 19.0% and 9.4%, respectively, P = 0.0008). However, there was no difference in phenotypic frailty (10.7% versus 11.2%, P = 0.27), and statin users had higher plasma prealbumin level than non-users (mean levels 257.9 and 246.3 mg/L, respectively, P = 0.034 adjusted for age, body mass index and C-reactive protein) implying better nutritional status. Despite morbidity difference, age-adjusted 7-year mortality was not different between the two groups (98 and 103 men among users and non-users of statins, respectively, hazard ratio 0.96, 95% confidence interval 0.72-1.30). CONCLUSIONS: our study suggests that male octogenarian statin users preserved resilience and survival despite multimorbidity, and this may be associated with better nutritional status among statin users.
Subject: 3121 General medicine, internal medicine and other clinical medicine
Cholesterol
CARDIOVASCULAR DISEASE
Metabolic
nutrition
PREALBUMIN
Older people
cholesterol
cardiovascular disease
metabolic
nutrition
prealbumin
older people
OLDER-ADULTS
PRIMARY PREVENTION
TRANSTHYRETIN
Referentgranskad: Ja
Licens: unspecified
Användningsbegränsning: openAccess
Parallelpublicerad version: acceptedVersion


Filer under denna titel

Totalt antal nerladdningar: Laddar...

Filer Storlek Format Granska
Statin_Treatment.pdf 235.5Kb PDF Granska/Öppna

Detta dokument registreras i samling:

Visa fullständig post